Because achievement of pCR is an appropriate surrogate for significantly improved long-term clinical outcomes in high-risk breast cancer subtypes (34), future studies validating this association of favorable ATM rs11212617 genotype with improvements in relapse-free survival after surgery in the METTEN study (and retrospective outcome analyses for other clinical trials) should definitely determine whether the rs11212617 C allele may lead to actionable modifications for prospective clinical planning in metformin-based anti-breast cancer approaches. Here, ATM is linked to breast carcinoma.